Postępy w Kardiologii Interwencyjnej

FIB-4 index and adverse outcomes of coronary artery disease: a systematic review and meta-analysis

Haoxuan Gao 1
,
Lujia Chai 2
,
Xiaolin Meng 3

  1. The Second Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China

  2. College of Mathematics and Statistics, Hainan University, Haikou, Hainan, China

  3. Supply Room, Jilin Jiangwan Trauma Hospital, Jilin City, Jilin Province, China

Adv Interv Cardiol

DOI: https://doi.org/10.5114/aic.2026.164916
Data publikacji online: 2026/09/21
Article file
FIB-4 index.pdf
  1. Wilhelmsen L, Rosengren A, Johansson S, Lappas G. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Göteborg, Sweden. Eur Heart J 1997; 18: 572-81.
  2. Caldonazo T, Rahouma M, Sandner S, et al. Association of subclinical liver fibrosis with death in patients with coronary artery disease: a post hoc analysis of the ISCHEMIA trial. J Am Heart Assoc 2025; 14: e040848.
  3. Demirtola A, Mammadli A, Çiçek G. Predictive value of the FIB-4 index in ST-elevation myocardial infarction patients: from admission to follow-up. Acta Cardiol 2025; 80: 387-93.
  4. Cao YX, Zhang M, Zhang HW, et al. Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: a prospective cohort study. Liver Int 2021; 41: 1294-304.
  5. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol 2021; 74: 790-9.
  6. Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7(27): iii-x, 1-173. doi:10.3310/hta7270.
  7. Ye Z, Xie E, Guo Z, et al. Association of liver fibrosis markers with mortality outcomes in patients with chronic kidney disease and coronary artery disease: insights from the NHANES 1999-2018 data. Cardiorenal Med 2025; 15: 153-63.
  8. Shibata N, Ito T, Morita Y, et al. Impact of the fibrosis-4 index in patients with ST-elevated myocardial infarction. Coron Artery Dis 2025; 36: 99-107.
  9. Zhu L, Chen Y, Li QQ, et al. Liver fibrosis scores as predictors of long-term outcomes in patients with ST-segment elevation myocardial infarction. Cardiovasc Innov Appl 2024; 9: 991.
  10. He HM, Zheng SW, Chen YN, et al. A comparison of the prognostic value of liver fibrosis scores in acute myocardial infarction patients with and without type 2 diabetes. Angiology 2024; 75: 219-30.
  11. Gaggini M, Minichilli F, Gorini F, et al. FIB-4 index and neutrophil-to-lymphocyte-ratio as death predictor in coronary artery disease patients. Biomedicines 2022; 11: 76.
  12. Cao M, Li T, Li Z, et al. A retrospective study on the relationship between fibrosis‑4 index and all‑cause mortality in patients with acute myocardial infarction. Exp Ther Med 2022; 24: 643.
  13. Liu H, Cao Y, Jin J, et al. Liver fibrosis scoring systems as novel tools for predicting recurrent cardiovascular events in patients with a prior cardiovascular event. Cardiol Discov 2021; 1: 214-22.
  14. Jin JL, Zhang HW, Cao YX, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int 2021; 15: 413-23.
  15. Chen Q, Li Q, Li D, et al. Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease. Atherosclerosis 2020; 299: 45-52.
  16. Yan Z, Liu Y, Li W, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Eur J Clin Invest 2022; 52: e13855.
  17. Oksen D, Gecit MH, Bulat Z, et al. Comparative prognostic performance of the FIB-4 index versus SYNTAX and GRACE scores in predicting major cardiovascular events in acute coronary syndrome. Adv Interv Cardiol 2025; 21: 332-40.
  18. Zhang J, Li L, Lin L, et al. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD. BMC Public Health 2025; 25: 2747.
  19. Morishita A, Oura K, Takuma K, et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int 2023; 17: 606-14.
  20. Yabiku K. Efficacy of sodium-glucose cotransporter 2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic steatohepatitis: a review of the evidence. Front Endocrinol 2021; 12: 768850.
  21. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications